A recent study published in Science Direct followed patients with metastatic renal cell carcinoma (RCC), who were ineligible for active surveillance, to determine whether a delay in receiving first-line treatment affected outcomes.
In the study, the overall median treatment delay was 6.3 weeks. Patients with bone metastases and advanced disease at diagnosis were more likely to experience a treatment delay. The researchers reported that there were no differences in progression-free survival and overall survival between patients who waited less than 6.3 weeks for first-line treatment compared with those who waited longer than 6.3 weeks.
In conclusion, the researchers reported that patients with metastatic RCC with bone metastases or advanced disease are most likely to experience a delay in receiving first-line treatment, but this delay does not appear to have an effect on survival outcomes.